On July 17, 2025, GSK plc reported that the US FDA advisory committee voted against the benefit/risk profile of Blenrep combinations for treating relapsed/refractory multiple myeloma, ahead of the final review on July 23, 2025. GSK remains confident in the drug's profile despite this setback.